| Literature DB >> 32228702 |
Zhang-Bo Cheng1,2, Han Chen3,4.
Abstract
BACKGROUND: Inflammatory response is activated during cardiopulmonary bypass (CPB), which may lead to acute respiratory distress syndrome (ARDS) and procalcitonin (PCT) increases during this inflammatory response. The objective of the study was to validate whether patients with higher serum PCT concentrations have a higher incidence of ARDS.Entities:
Keywords: Acute respiratory distress syndrome; Cardiopulmonary bypass; Procalcitonin
Mesh:
Substances:
Year: 2020 PMID: 32228702 PMCID: PMC7106626 DOI: 10.1186/s40001-020-00409-2
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Fig. 1Outline of the screening and follow-up. PCT procalcitonin, PAC pulmonary artery catheter
Demographic and surgical characteristics at baseline
| PCT elevated | Control | ||
|---|---|---|---|
| Age (years, old) | 61.0 ± 9.9 | 60.8 ± 10.3 | 0.904 |
| Male, | 41 (64.1) | 119 (51.3) | 0.070 |
| Smoker, | 14 (21.9) | 52 (22.4) | 0.927 |
| Coexisting conditions | |||
| Hypertension, | 30 (46.9) | 117 (50.4) | 0.614 |
| Diabetes mellitus, | 18 (28.1) | 65 (28) | 0.986 |
| Coronary artery disease, | 52 (81.3) | 176 (75.9) | 0.364 |
| NYHA grade III–IV, | 34 (53.1) | 132 (56.9) | 0.590 |
| Liver disease, | 3 (4.7) | 5 (2.2) | 0.269 |
| Preoperative drug therapy | |||
| ACEI, | 16 (25) | 46 (19.8) | 0.368 |
| Beta-blocker, | 21 (32.8) | 71 (30.6) | 0.735 |
| Calcium channel blocker, | 18 (28.1) | 59 (25.4) | 0.664 |
| Aspirin, | 32 (50) | 99 (42.7) | 0.296 |
| Aspirin + clopidogrel, | 20 (31.3) | 56 (24.1) | 0.249 |
| Preoperative troponin I (ng/mL) | 0.07 ± 0.04 | 0.08 ± 0.06 | 0.336 |
| Preoperative Nt-pro-BNP (pg/mL) | 826 ± 301 | 772 ± 294 | 0.201 |
| Surgery type | 0.080 | ||
| CABG, | 52 (81.3) | 155 (66.8) | 0.078 |
| Valve replacement, | 9 (14.1) | 61 (26.3) | 0.123 |
| Other, | 3 (4.7) | 16 (6.9) | > 0.999 |
| Operation duration (min) | 305.7 ± 63.5 | 264.4 ± 51.1 | < 0.001* |
| CPB time (min) | 147.2 ± 32 | 135.6 ± 22.3 | 0.008* |
| Aortic clamping time (min) | 84.5 ± 17.6 | 78.4 ± 18.2 | 0.017* |
| Intraoperative fluid balance (mL) | 124 ± 203 | 109 ± 229 | 0.626 |
| RBC infusion (mL) | 259 ± 316 | 183 ± 215 | 0.530 |
| FFP infusion (mL) | 294 ± 325 | 215 ± 228 | 0.306 |
PCT procalcitonin, NYHA New York Heart Association, ACEI angiotensin converting enzyme inhibitor, Nt-pro-BNP N-terminal pro-B-type natriuretic peptide, CABG coronary artery bypass grafting, CPB cardiopulmonary bypass, RBC red blood cell, FFP fresh frozen plasma
* p < 0.05
aIncluding adult congenital heart procedure, great artery surgery and combined surgery
Fig. 2Kaplan–Meier survival estimates through postoperative day 7. a Probability of being ARDS free through postoperative day 7. b Probability of being free of moderate-to-severe ARDS through postoperative day 7
Outcomes data
| Overall population | PCT elevated | Control | ||
|---|---|---|---|---|
| 1st postoperative day fluid balance (mL) | 672 ± 276 | 663 ± 248 | 727 ± 322 | 0.051 |
| Nt-pro-BNP (pg/mL) | 2699 ± 1373 | 2836 ± 1403 | 2662 ± 1365 | 0.372 |
| PCT (ng/mL) | 5.63 ± 6.34 | 16.23 ± 5.9 | 2.70 ± 1.43 | < 0.001* |
| WBC (*109/L) | 13.6 ± 2.2 | 13.8 ± 2.8 | 13.5 ± 2.0 | 0.532 |
| VIS | 16.2 ± 9.6 | 16.0 ± 14.2 | 16.2 ± 8.0 | 0.898 |
| P/F ratio | 367 ± 66 | 334 ± 88 | 375 ± 56 | 0.001* |
| Severity of ARDS | < 0.001* | |||
| No ARDS, | 269 (90.9) | 50 (78.1) | 219 (94.4) | < 0.001* |
| Mild ARDS, | 19 (6.4) | 7 (10.9) | 12 (5.2) | 0.576 |
| Moderate ARDS, | 7 (2.4) | 6 (9.4) | 1 (0.4) | < 0.001* |
| Severe ARDS, | 1 (0.3) | 1 (1.6) | 0 | 0.864 |
| MV duration (day) | 1.7 ± 1.7 | 2.6 ± 3.0 | 1.4 ± 0.9 | 0.002* |
| ICU stay (day) | 2.0 ± 2.4 | 1.7 ± 1.4 | 3.3 ± 4.3 | < 0.001* |
| Mortality, | 1 (0.3) | 1 (1.6) | 0 (0) | 0.490 |
| Renal failure, | 4 (1.4) | 2 (3.1) | 2 (0.8) | 0.165 |
| Pneumonia, | 6 (2.0) | 4 (6.3) | 2 (0.8) | 0.027* |
PCT procalcitonin, Nt-pro-BNP N-terminal pro-B-type natriuretic peptide, WBC white blood cell, VIS vasoactive-inotropic score, ARDS acute respiratory distress syndrome, MV mechanical ventilation
* p < 0.05
Fig. 3Receiver-operating characteristics curve assessing the predictive performance of PCT on the development of ARDS
Value of PCT in predicting ARDS
| For ARDS | For moderate-to-severe ARDS | |
|---|---|---|
| Sensitivity (95% CI) | 59.3% (38.8%, 77.6%) | 100% (63.1%, 100%) |
| Specificity (95% CI) | 81.4% (76.2%, 85.9%) | 79.9% (74.8%, 84.3%) |
| Positive predictive value (95% CI) | 0.242 (0.145, 0.364) | 0.121 (0.054, 0.225) |
| Negative predictive value (95% CI) | 0.952 (0.916, 0.976) | 1.0 (0.984, 1) |
| Positive likelihood ratio (95% CI) | 3.19 (2.1, 4.8) | 4.97 (3.9, 6.2) |
| Negative likelihood ratio (95% CI) | 0.50 (0.3, 0.8) | < 0.01 |
Using a cut-off value of 6.5 ng/mL
ARDS acute respiratory distress syndrome